Redeye Feed

2025-02-20 14:59:00 Cinclus Pharma Q4 - Validation through market approval

2025-02-20 08:17:00 AroCell Q4 - Positive development continues

2025-02-20 08:05:00 Nanologica Q4 2024 - Stepping into the next phase

2025-02-20 08:03:00 Raketech - Solid margin but soft growth outlook with limited visibility

2025-02-20 08:02:00 Nekkar - Q4 Review – On Course

2025-02-20 07:59:00 Surgical Science Q4 2024 - Growth should ramp in 2025e, margins might lag

2025-02-19 18:46:00 Starbreeze - Cash postive agreements with optionality

2025-02-19 11:46:00 BioArctic - A bit stronger Q4 than expected, BMS deal a validation of BT technology

2025-02-19 07:38:00 Truecaller - Strong year-end and more to come

2025-02-19 07:36:00 Medivir Q4 2024 - Phase IIb Trial Design Set

2025-02-19 07:20:00 SynAct Q4 2024 - Successful Rights Issue Funds 2025

2025-02-19 07:19:00 CoinShares - Well positioned versus US peers

2025-02-19 07:17:00 Smart Eye - Even better than it looks

2025-02-19 07:07:00 Gentoo Media - Stable growth outlook

2025-02-18 08:34:00 Nitro Games - Executing on its multi-platform strategy

2025-02-18 08:34:00 Corline Biomedical Q4 - Focus on Kardium’s market launch

2025-02-18 08:33:00 Arise - Leaves a challenging 2024 for a potentially prosperous 2025

2025-02-17 08:33:00 Sedana Medical Q4 - Slightly better than expected

2025-02-17 08:30:00 Embracer - Solid performance in PC/Console

2025-02-17 08:28:00 Genovis Q4 2024 - Solid but softer than we estimated

2025-02-17 08:27:00 Doro - A solid and stable finish to 2024

2025-02-17 08:26:00 AcouSort Q4 - All eyes forward

2025-02-17 08:25:00 Safeture - Lower targets but solid foundation

2025-02-17 08:23:00 Acconeer - Robust financing mitigates the downside risks

2025-02-17 08:22:00 BeammWave - Shifting to a new phase

2025-02-17 08:21:00 Carasent - Back in Shape in 2024 – More to Come

2025-02-17 08:19:00 Fortnox - Business Insights and ARPC in Focus

2025-02-17 08:18:00 SSH Communications Security - Strong close of the year

2025-02-14 16:50:00 CombinedX - Stable Performance in Soft Market

2025-02-14 12:56:00 Powercell - Solid finish to 2024

2025-02-14 12:55:00 Active Biotech Q4 2024 - Funded through 2025

2025-02-14 09:58:00 Devyser Q4 - Looking strong on corrected numbers

2025-02-14 09:57:00 Stille Q4 2024 - Bags another strong quarter

2025-02-14 09:56:00 Acarix Q4 - Approaching ramp-up

2025-02-14 09:55:00 Catella - Strong end to a tough year

2025-02-14 09:54:00 Polygiene Group - Scaling up with stronger margins

2025-02-14 09:53:00 Thunderful Group - Leaving a challenging 2024 behind

2025-02-14 09:52:00 Invisio - Strong outlook for 2025 and increased addressable market

2025-02-14 09:51:00 G5 Entertainment - Signs of growth improvement

2025-02-14 09:50:00 Alligator Bioscience Q4 2024 - Can the Rights Issue Fund Alligator to a Deal?

2025-02-14 09:49:00 Mendus Q4 2024 - Getting closer to pivotal-stage readiness

2025-02-14 09:48:00 Optomed Q4 - Quarter in line with expectations

2025-02-14 09:47:00 Lytix Biopharma - Funded Well into 2026

2025-02-14 09:46:00 SenzaGen Q4 - Leaving Q4 behind and looking forward to a new year

2025-02-14 09:45:00 IRLAB Q4 - Upcoming Pirepemat readout in focus

2025-02-13 11:55:00 Xspray Pharma Q4 2024 - In anticipation of an eventful year

2025-02-13 11:51:00 Sprint Bioscience Q4 - Confident expansion

2025-02-13 11:47:00 Neola Medical Q4 - Vital clinical data incoming

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden